Thymalin is a complex of peptides extracted from the thymus gland of calves. It is registered as a medicine in Russia but is not FDA-approved, and no approved medicine in the United States contains it.
The thymus is a small organ in the chest that helps T cells, a type of white blood cell, mature. Thymalin is not a single defined molecule, which sets it apart from synthetic thymus-related peptides such as thymosin alpha-1. The name is also sometimes confused with thymulin, a different, single peptide hormone made by the thymus.
Thymalin was developed in the Soviet Union by Vladimir Morozov and Vladimir Khavinson, who in 1974 described a method for isolating low-molecular-weight peptides from calf thymus. According to Khavinson's group, it was registered by the USSR Ministry of Health in 1982 as the first of a class of products they call peptide bioregulators. In Russia it has been used as an immunomodulator, including in people with cancer.
Registration in one country does not transfer to another. In the United States, a drug must be approved by the FDA before it can be legally marketed as a medicine.
Most published research on Thymalin comes from Russian groups linked to its developers, and much of it appears in Russian-language journals.
In a 2003 paper in the journal Neuroendocrinology Letters, Khavinson and Morozov reported lower death rates over about six years among older adults given Thymalin, a pineal gland extract called epithalamin, or both, compared with a control group. The authors were also the developers of these products, and the findings have not been confirmed in large independent trials of the kind the FDA requires.
Because Thymalin is an animal-derived extract, its exact makeup is harder to define than that of a single synthetic peptide, which makes results harder to compare across studies.
Current status: Not FDA-approved.
Thymalin is not the active ingredient in any FDA-approved medicine, and the FDA has not found it safe and effective for any use in people. It does not appear in any category of the FDA's 503A nomination lists (as updated May 14, 2026) and is not on the 503A bulks list, so it does not meet the conditions for 503A compounding.
It is also not a dietary supplement. Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
The FDA has not published a safety assessment of Thymalin, and U.S. regulators have not reviewed its Russian product information. Without controlled trials that meet U.S. standards, its safety profile in people is not well established.
Thymalin is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List. Athletes should confirm the status of any substance with their anti-doping organization.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply Thymalin, and we do not point readers to anyone who does.
For personal medical questions, including questions about immune health, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Related profiles: thymosin alpha-1, epitalon and pinealon. You can also read whether peptides are legal in the U.S.